Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan‐cancer. Issue 9 (23rd July 2022)

• Record Type: Journal Article
• Authors: Shen, Yiming; Wei, Zhengyu; Zhou, Chongchang; Song, Jiangping; Wang, Jianing; Wang, Jiada; Wu, Linrong; Fang, Shenzhe; Shen, Zhisen
• Is Part Of: Journal of clinical laboratory analysis. Volume 36:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-23
• Subjects: ARSI -- drug sensitivity -- GSEA -- GSVA -- HNSC -- prognosis -- tumor microenvironment; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.24600
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract: Background: Sulfatase gene family members mediate various biological functions in tumor stroma and tumor cell environments. However, the expressions and prognostic value of Arylsulfatase I ( ARSI ), a sulfatase gene family member, in head and neck squamous cell carcinoma (HNSC) have not been fully established. Methods: Arylsulfatase I expressions in pan‐cancer were profiled using publicly available databases. Then, univariate Cox regression, Kaplan–Meier, and the Pearson's correlation analyses were performed to determine correlations between ARSI expressions and cancer prognosis, immune cell status, and drug sensitivity. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were used to assess the potential mechanisms underlying ARSI functions in HNSC. Results: Arylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC. Elevated ARSI levels were associated with worse prognostic outcomes in HNSC patients. In addition, GSVA and GSEA showed that ARSI was highly involved in tumor cell escape and inflammatory responses. Expressions of ARSI negatively correlated with tumor mutation burden or microsatellite instability and positively correlated with immune‐related genes. Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939. Conclusion: Arylsulfatase I is a promising prognostic and therapeutic target for HNSC. Abstract : The work flow of the study. TCGA; The Cancer Genome Atlas, GTEx; Genotype‐Tissue Expression, GSVA; Gene Set Variation Analysis, GSEA, Gene Set Enrichment Analysis, ARSI ; Arylsulfatase I, MSI; Microsatellite instability, TMB; Tumor mutational burden.